LIMITLESS PATHWAYS
A parent-led 501(c)(3) pending organization dedicated to raising awareness, supporting families, and driving research forward.
Our Mission
I’m Dina Friedman, a clinical psychologist, the founder of Limitless Pathways, and the mother of a daughter with a rare, complex neurodevelopmental disease that took 18 years to diagnose. Our journey has often felt isolating and unrecognized, with moments of pain that shaped my understanding of what families truly need. Those gaps — the loneliest and most uncertain moments — inspired me to build pathways that offer clearer guidance, connection, and hope to others facing similar challenges. Limitless Pathways was created to fill the gaps that families like ours have faced for far too long — transforming what was missing into meaningful support. We work to reshape the landscape of care for individuals with neurodevelopmental conditions and their families by offering practical solutions, collaborative programs, and meaningful opportunities for growth, confidence, and connection. These pathways can take many forms: therapeutic tools, emotional support, independence-building skills, community connections, and more. Our role is to help families recognize these avenues, nurture them, and walk alongside them as they unfold — while expanding awareness and advancing fundraising that supports innovative resources and research. If you continue to believe that hope is possible — even when pathways are hidden or just beginning to emerge — then you understand the heart of this work.
I am here today not only as Sienna’s mother, but also as a voice for all CAMK2 families. Our children’s stories carry shared themes—misdiagnosis, struggle, resilience, and the desperate search for effective treatments. I make this request before you to advocate on behalf of my daughter and every CAMK2 child and family, so that their voices are heard, their suffering acknowledged, and their hope for timely treatment is met with urgent action.
Our Founder
Our Why
What is CAMK2?
CAMK2 is a rare genetic condition, with about 300 diagnosed patients worldwide, though the true number is likely higher due to under-testing and misdiagnosis. CAMK2 mutations cause dysregulation of calcium signaling, leading to physical, developmental, and behavioral symptoms.
While there are no current targeted treatments, scientists and physicians are optimistic—some predict targeted therapies could be available within three years. A landmark study in Rotterdam demonstrated complete reversal of symptoms in mice, offering real hope for translational therapies.
CAMK2 is typically a single gene mutation and is usually not inherited, which opens the door for precision genetic or molecular treatments. Progress in CAMK2 research will likely benefit related disorders such as GRIN and SYNGAP.
Subscribe to Our Newsletter
Strength in numbers, strength in our connections. We exist to bring hope and knowledge to families, and to advocate for research, diagnostics and precision medicine treatment and therapies.
Contact Us
Whether its an inquiry for support, information, or you would like to join the mission please use the form below
